Adrenal Function in GHD Children
Evaluation of Adrenal Function Before and After GH Treatment in GHD Affected by GH Deficiency
1 other identifier
observational
30
1 country
1
Brief Summary
To evaluate in children affected by idiopathic GHD the adrenal function both at baseline and after 6 and 12 months of GH treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started May 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 30, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2017
CompletedFirst Submitted
Initial submission to the registry
May 26, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
May 30, 2017
CompletedFirst Posted
Study publicly available on registry
June 29, 2017
CompletedJune 29, 2017
June 1, 2017
11 months
May 26, 2017
June 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Evaluation of adrenal function in GHD children at baseline and in control group
We will evaluate through insulin tolerance test the response of serum cortisol levels in GHD children at diagnosis (before start of GH therapy) and in controls subjects
baseline
Change in adrenal function in GHD children during GH therapy
We will evaluate through insulin tolerance test the response of serum cortisol levels in GHD children after 6 and 12 months of GH therapy
6 and 12 months
Study Arms (2)
GHD children
about 30 prepubertal children affected by overt idiopathic GHD
controls
about 30 prepubertal children with constitutional short stature without endocrine disease
Interventions
Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
Eligibility Criteria
30 consecutive children with short stature and overt idiopathic GHD and 30 children with constitutional short stature without endocrine disease
You may qualify if:
- prepubertal children with overt idiopathic growth hormone deficiency
You may not qualify if:
- Children with organic growth hormone deficiency or under treatment with glucocorticoids
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Endocrinology - University of Palermo
Palermo, 90127, Italy
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Carla Giordano
Study Record Dates
First Submitted
May 26, 2017
First Posted
June 29, 2017
Study Start
May 30, 2016
Primary Completion
May 1, 2017
Study Completion
May 30, 2017
Last Updated
June 29, 2017
Record last verified: 2017-06
Data Sharing
- IPD Sharing
- Will not share
IPD will be available just for our study